HPS Pharmacies wish to advise that Phebra is experiencing a supply interruption for Glaumox® as follows:
Acetazolamide (as sodium) 500 mg
This long-term supply interruption is expected to resolve towards the middle of 2024.
An internationally registered brand of acetazolamide 500mg vials has been approved for supply under Section 19A of the Therapeutic Goods Act 1989. This product is identical in active ingredient, strength, and formulation to the Australian registered product and all packaging is in English.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Phebra on 1800 720 020 or your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates